SCHEMBL387489

SCHEMBL387489

O=c1[nH]nccc1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethylbenzene SCHEMBL28012872 0.80 ALDH1A1 (0.45)
SCHEMBL1456892 0.74 HCAR2 (0.41)
SCHEMBL28815828 0.70 RPS6KA3 (0.47)
SCHEMBL390310 0.70
SCHEMBL392004 0.70
SCHEMBL1994489 0.70
SCHEMBL18797097 0.70
SCHEMBL8644938 0.70
SCHEMBL5671452 0.70
SCHEMBL725340 0.70 HCAR2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0382634-B1 Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI ELF (FR) 1994-05-04 EP claimed
JP-6009574-A None JP disclosed
US-20230340083-A1 ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION Vir Biotechnology, Inc. 2023-10-26 US disclosed
CN-116917315-A Antibodies and methods for treating influenza A infection 维尔生物科技有限公司 2023-10-20 CN disclosed
EP-4259655-A1 ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION VIR Biotechnology, Inc. (US) 2023-10-18 EP disclosed
EP-4114361-A1 ORAL SOLID PREPARATIONS Takeda Pharmaceutical Company Limited (JP) 2023-01-11 EP disclosed
US-20220298230-A1 ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS THE ROCKEFELLER UNIVERSITY (US) 2022-09-22 US disclosed
CN-115052630-A Compositions and methods for treating influenza a infection 维尔生物科技有限公司 2022-09-13 CN disclosed
US-20220226470-A1 ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION Vir Biotechnology, Inc. 2022-07-21 US disclosed
EP-4021502-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION VIR Biotechnology, Inc. (US) 2022-07-06 EP disclosed
US-5631255-A AFFINITY FOR CHOLINERGIC RECEPTORS, TREATMENT OF COGNITIVE AND MEMORY DISORDERS, AND DEGENERATIVE SYNDROMES SANOFI (FR) 1997-05-20 US disclosed
CN-1141879-A Process for preparation of phosphorous sulfide MONSANTO CO (US) 1997-02-05 CN disclosed
EP-0752998-A1 THIONATION PROCESS USING ELEMENTAL PHOSPHORUS AND SULFUR MONSANTO COMPANY (US) 1997-01-15 EP disclosed
US-5461053-A Cognition activator SANOFI (FR) 1995-10-24 US disclosed
WO-1995026357-A1 THIONATION PROCESS USING ELEMENTAL PHOSPHORUS AND SULFUR MONSANTO COMPANY (US) 1995-10-05 WO disclosed
EP-0608215-A1 QUINOBENZOXAZINE, QUINOBENZOTHIAZINE, AND PYRIDO-ACRIDINE ANTINEOPLASTIC AGENTS ABBOTT LABORATORIES (US) 1994-08-03 EP disclosed
JP-H069574-A HERBICIDAL N-CYANOPYRIDAZINONE AGROLINZ AGRARCHEMIKALIEN GMBH 1994-01-18 JP disclosed
EP-0608215-A4 QUINOBENZOXAZINE, QUINOBENZOTHIAZINE, AND PYRIDO-ACRIDINE ANTINEOPLASTIC AGENTS. ABBOTT LAB (US) 1993-11-11 EP disclosed
US-5081119-A Muscarinic antagonists, dememtia, Alzheimer,s SANOFI (FR) 1992-01-14 US disclosed
US-4977152-A For alzheimer*s disease SOCIETE ANONYME: SANOFI (FR) 1990-12-11 US disclosed